Document:

<PAGE>

                                                                   EXHIBIT 10.1

             AMENDMENT NO. 1 TO THE COMMON STOCK PURCHASE AGREEMENT

                                  July 10, 2006

      This Amendment No. 1 (this "Amendment") to the Common Stock Purchase
Agreement (the "Agreement") dated March 24, 2006, by and between Biotech Shares
Ltd., an entity organized and existing under the laws of the Isle of Man (the
"Investor"), and Idera Pharmaceuticals, Inc., a corporation organized and
existing under the laws of the State of Delaware (the "Company"), is entered
into as of the 10th day of July 2006.

      WHEREAS, under the terms of the Agreement the Company has the right to
sell to the Investor up to $2,500,000 of the Company's Common Stock prior to the
effectiveness of the Pre-Issuance Registration Statement (as such term is
defined in the Agreement);

      WHEREAS, the Company and the Investor have agreed pursuant to an amendment
to the Registration Rights Agreement (as defined in the Agreement) that the
Company shall not be obligated to file the Pre-Issuance Registration Statement
with the United States Securities and Exchange Commission until August 14, 2006;
and

      WHEREAS, the Company desires to sell to the Investor in excess of
$2,500,000 of the Company's Common Stock prior to such date;

      WHEREAS, in order to allow the Company to sell the desired number of
shares of its Common Stock prior to such date, the Company and the Investor
agree that certain terms of the Agreement must be amended.

      NOW, THEREFORE, the Company and the Investor agree as follows:

Amendment to $2,500,000 Purchase Amount Limitation.

1.    The second sentence of Section 3(a) of the Agreement is hereby deleted in
      its entirety and the following is substituted in lieu thereof:

      "(a) If the Purchase Notice involves a Purchase Amount, which when
      aggregated with the Purchase Amount of Common Stock previously sold to the
      Investor hereunder exceeds $3,500,000, the Company shall confirm in such
      Purchase Notice that a registration statement (the "Pre-Issuance
      Registration Statement") covering the resale of the shares of Common Stock
      to be issued on such closing date has been declared and is effective and
      that the certificates representing such shares shall not bear a restricted
      securities legend."

2.    Section 3(d) of the Agreement is hereby deleted in its entirety and the
      following is substituted in lieu thereof:

      "(d) Notwithstanding the foregoing, the Investor shall have no obligation
      hereunder to purchase any shares of Common Stock if the Purchase Amount of
      such shares, when aggregated with the Purchase Amount of Common Stock
      previously sold to the Investor under this Agreement, exceeds $3,500,000
      unless the Pre-Issuance Registration Statement

<PAGE>

      has been declared and is effective and the certificates representing such
      shares will not bear a restricted securities legend."

Reverse Split Purchase Price.

In order to reflect the reverse stock split effected on June 30, 2006, Section
3(b) of the Agreement is hereby deleted in its entirety and the following is
substituted in lieu thereof:

      "(b) The number of shares of Common Stock to be issued in connection with
      a Purchase Notice shall be determined by dividing (1) the Purchase Amount
      specified in the Purchase Notice by (ii) the greater of (A) $5.12 and (B)
      80% of the volume-weighted average of the Closing Prices (as defined
      below) of the Common Stock for the five consecutive Trading Days (as
      defined below) immediately preceding the date that the Company sends such
      Purchase Notice to the Investor."

Purchase Notice.

1.    Attached hereto as Exhibit A is a Purchase Notice providing for the sale
      of $3,500,000 of Common Stock to the Investor at a closing to be held on
      July 24, 2006, pursuant to the terms of the Agreement, as amended by this
      Amendment.

2.    The Investor acknowledges the delivery of the Purchase Notice as of the
      date hereof.

Miscellaneous

1.    This Amendment may be executed in identical counterparts, each of which
      shall be deemed an original but all of which shall constitute one and the
      same agreement. This Amendment, once executed by a party, may be delivered
      by facsimile transmission of a copy of this Amendment bearing the
      signature of the party so delivering this Amendment.

2.    Except as expressly modified by or pursuant to this Amendment, the Common
      Stock Purchase Agreement shall remain in full force and effect without any
      other change or modification.

<PAGE>

IN WITNESS WHEREOF, the parties have caused this Amendment No. 1 to the
Agreement to be duly executed as of the day and year first above written.

                             COMPANY:

                             IDERA PHARMACEUTICALS, INC.

                             By:         /s/ Sudhir Agrawal
                                 ------------------------
                                 Name:   Sudhir Agrawal
                                 Title:  Chief Executive Officer

                             INVESTOR:

                             BIOTECH SHARES LTD.

                             By:         /s/ Oussama Salam
                                 Name:   Oussama Salam
                                 Title:  Director

<PAGE>

                                    Exhibit A

                           IDERA PHARMACEUTICALS, INC.
                               345 VASSAR STREET
                            CAMBRIDGE, MA 02139-4818

                                                                   July 10, 2006

Biotech Shares Ltd.
St. James's Chambers
64A Athol Street
Isle of Man IM1 1JE

         Re:      Purchase Notice

Gentlemen:

         Pursuant to and in accordance with the terms of that certain Common
Stock Purchase Agreement, dated March 24, 2006 (the "PURCHASE AGREEMENT"), as
amended, by and between Biotech Shares Ltd. (the "INVESTOR") and Idera
Pharmaceuticals, Inc. (the "COMPANY"), the Company hereby provides notice (the
"PURCHASE NOTICE") to the Investor that the Company has duly elected to issue
and sell to the Investor, and the Investor is hereby obligated to purchase from
the Company, the number of shares of common stock of the Company, US$0.001 par
value per share (the "COMMON STOCK"), set forth below, on such date and for such
dollar amount as is set forth below (the "DRAWDOWN"):

1.    The number of shares of Common Stock to be issued to the Investor on the
      Drawdown Date (as defined below) to its account with First National Bank
      S.A.L.: 683,593 the "SHARES").

2.    The dollar amount of the Shares: US$3,499,996.16 (the "PURCHASE AMOUNT" or
      "DRAWDOWN AMOUNT").

3.    The closing date for the Drawdown (and the date on which payment of the
      Purchase Amount shall be made to the Company): July 24, 2006 (the
      "DRAWDOWN DATE").

4.    The price per share of the Common Stock used to calculate the number of
      Shares to be issued on the Drawdown Date: US$5.12 per share of Common
      Stock.

      The Company hereby confirms that the Shares and the Drawdown Amount are in
compliance with all of the terms and conditions of the Purchase Agreement.

                             IDERA PHARMACEUTICALS, INC.

                             By:
                                 -------------------------
                                 Name:
                                 Title:CLOSING
AGREEMENT

CLOSING AGREEMENT (this
‘‘Agreement’’), dated as of November 9,
2006, by and among MDwerks, Inc., a Delaware corporation, with
headquarters located at 1020 NW 6th Street, Suite I,
Deerfield Beach, FL 33442 (the
‘‘Company’’), and Gottbetter Master,
Ltd. (‘‘Buyer’’).

W I T NE S S E T H:

WHEREAS:

A.    In connection with the
Securities Purchase Agreement by and among the parties hereto dated as
of October 19, 2006 (the ‘‘Securities Purchase
Agreement’’), the Company has agreed, upon the terms
and subject to the conditions set forth in the Securities Purchase
Agreement, to issue and sell to Buyer (i)  convertible notes of
the Company (the ‘‘Notes’’) which will,
among other things, be convertible into shares of the Company's
common stock (‘‘Common Stock’’), par
value $0.001 per share (the ‘‘Conversion
Shares’’) in accordance with the terms of the Notes,
and (ii) warrants (the ‘‘Warrants’’)
which will be exercisable to purchase a number of shares of Common
Stock in accordance with the terms of the Warrants (the
‘‘Warrant Shares’’).

B.    To
induce the Buyer to execute and deliver the Securities Purchase
Agreement, at the Initial Closing (as defined in the Securities
Purchase Agreement) which Initial Closing occurred on October 20, 2006,
the parties hereto executed and delivered a Registration Rights
Agreement (the ‘‘Registration Rights
Agreement’’), pursuant to which the Company has agreed
to provide certain registration rights with respect to the Conversion
Shares and the Warrant Shares.

C.    The Buyers desire to
acknowledge that all of the Company's obligations with respect to
the filing of the Registration Statement set forth in Sections 2 and 3
of the Registration Rights Agreement have been satisfied by the filing
of the Registration Statement attached hereto as Exhibit A, which
Registration Statement includes 2,777,778 Conversion Shares which may
be issued upon conversion of the Notes.

D.    The Buyers
desire to waive the requirement contained in the Registration Rights
Agreement for the company to register for resale the shares of Common
Stock into which the Warrants issued to Buyers are exercisable.

D.    The Buyers desire to acknowledge that the condition for the
first Additional Closing Date set forth in paragraph 7(b)(xi) of the
Securities Purchase Agreement has been satisfied by the filing of the
Registration Statement attached hereto as Exhibit A.

E.    The
Buyers desire to acknowledge that it will not be an event of default
under the Notes or a breach of the Registration Rights Agreement or the
Securities Purchase Agreement, if the SEC determines that the number of
shares of Common Stock which the Company may register on Form SB-2
pursuant to Section 415 of the Securities Act is less than the number
of shares required to be registered pursuant to the Registration Rights
Agreement and the Securities Purchase Agreement (a
‘‘Rule 415 Condition’’); provided that the
Company comply with the terms and conditions contained
herein.

1

F.    Unless otherwise indicated,
capitalized terms in this Agreement not defined herein shall have the
meanings ascribed to them in the Securities Purchase Agreement, the
Registration Rights Agreement and the Notes.

NOW, THEREFORE, in
consideration of the premises and the mutual covenants contained herein
and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Company and each of the Buyers
hereby agree as follows:

1.    Decrease in Required
Registration Amount. Effective as of the date hereof, Section 1(l)
of the Registration Rights Agreement is hereby amended and restated to
read as follows:

l.    ‘‘Required
Registration Amount’’ means 2,777,778 Conversion Shares
issuable pursuant to the Notes, all subject to adjustment as provided
in Section 2(e) (without regard to any limitations on conversion of the
Notes); provided, however, in the event of a Rule 415 Condition (as
defined in that certain Closing Agreement, dated November 9, 2006), the
Required Registration Amount shall be reduced to the number of
Conversion Shares equal to the maximum amount of shares allowed to be
registered by the SEC multiplied by 0.5025, which represents
Buyer's pro rata portion of all shares of Common Stock which the
Company is required to register for resale.

2.    The Buyers
hereby acknowledge that all of the Company's obligations with
respect to the filing of the Registration Statement set forth in
Sections 2 and 3 of the Registration Rights Agreement have been
satisfied by the filing of the Registration Statement attached hereto
as Exhibit A.

3.    The Buyers hereby acknowledge that all the
conditions for the first Additional Closing Date set forth in paragraph
7(b)(xi) of the Securities Purchase Agreement have been satisfied by
the filing of the Registration Statement attached hereto as Exhibit
A.

4.    This Agreement shall constitute an amendment or
waiver of the Securities Purchase Agreement pursuant to the provisions
of the Section 9(e) thereof. This Agreement shall also constitute an
amendment or waiver of the Registration Rights Agreement pursuant to
the provisions of Section 10 thereof.

5.    This Agreement
shall be binding upon all successors and assignees of the Company and
Buyer.

[Signature Page Immediately Follows
This Page]

2

IN WITNESS WHEREOF, each Buyer and the
Company have caused their respective signature page to this Closing
Agreement to be duly executed as of the date first written above.

		COMPANY:
 MDWERKS, INC.

			
		By: 	/s/ Howard Katz

Name:Howard Katz
 Title: Chief Executive Officer

IN WITNESS
WHEREOF, each Buyer and the Company have caused their respective
signature page to this Closing Agreement to be duly executed as of the
date first written above.

		BUYERS:

GOTTBETTER CAPITAL MASTER, LTD.

			
		By: 	/s/ Adam S. Gottbetter

Name:Adam S. Gottbetter
 Title:
Director

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}]]